drugset / Trial / NCT00900237

Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine

NCT00900237

Phase 1 Completed 14 enrolled Bial - Portela C S.A.
RandomizedParallel-groupOpen-labelTreatment

Summary

This purpose of this study is to measure the concentrations of two anti-epileptic drugs (Eslicarbazepine acetate and oxcarbazepine) and their metabolites in the cerebrospinal fluid and blood plasma of healthy subjects and also to assess how these drugs are tolerated.

Timeline

Start
2008-11
Primary completion
2008-12
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Eslicarbazepine acetate Unknown 1200 mg Oral
Comparator Oxcarbazepine Small molecule 600 mg

Indications